Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04820192 · ClinicalTrials.gov registry record
Craniosacral Therapy for Concussion Symptoms
A clinical trial of Post-Concussion Syndrome, sponsored by Special Therapies.
- Completed
- Registry status
- 67
- Enrollment target
- 1
- Study location
NCT04820192: Completed study of Post-Concussion Syndrome, sponsored by Special Therapies.
NCT04820192 is a study of Post-Concussion Syndrome that has completed, run by Special Therapies. The registered enrollment target is 67 participants, above the 55-participant average among 14 other Post-Concussion Syndrome trials with a reported enrollment target (22% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04820192, a study of Post-Concussion Syndrome, has completed, sponsored by Special Therapies.
- COMPLETED
- Registry status
- 67 participants
- Enrollment target
- 1
- Study location
Study Summary
This study investigated the utilization of CranioSacral Therapy (CST) in patients with Post-Concussion Syndrome (PCS) and capture patient-reported perceptions of their lived experiences of treatment effect upon their symptoms. The first part part was a 10 year chart review of patients who sought out CST to capture data from the medical records. The second part was an anonymous post treatment survey.
Primary Outcome
Data extracted from medical chart to study how many sessions patients participated in (addressing their presenting symptoms). Number of sessions were recorded.
Conditions Studied
Interventions
- OTHER Craniosacral Therapy
Study Locations (1)
Wisconsin
- Special Therapies, Inc. - Waukesha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2018-01-15 |
| Est. Completion | 2019-07-30 |
What the finished NCT04820192 record still lists
NCT04820192 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 67 participants, a relatively small participant target, above the 55-participant average among 14 other Post-Concussion Syndrome trials with a reported enrollment target (22% higher).
The record links to 1 condition, with Post-Concussion Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Craniosacral Therapy is the first listed.
NCT04820192 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT04820192 about?
NCT04820192 is a clinical study titled "Craniosacral Therapy for Concussion Symptoms". This study investigated the utilization of CranioSacral Therapy (CST) in patients with Post-Concussion Syndrome (PCS) and capture patient-reported perceptions of their lived experiences of treatment effect upon their symptoms. The first part part was a 10 year chart review of patients who sought out...
What is the current status of trial NCT04820192?
This trial is currently completed. The enrollment target is 67 participants. The study started on 2018-01-15. Estimated completion is 2019-07-30.
What conditions does trial NCT04820192 study?
This clinical trial studies the following conditions: Post-Concussion Syndrome.
What interventions are being tested in trial NCT04820192?
The interventions under investigation include: Craniosacral Therapy (OTHER).
Who is sponsoring clinical trial NCT04820192?
This trial is sponsored by Special Therapies, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04820192 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post-Concussion Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04820192's enrollment target sits among peer trials
67 5th of 14 higher than 10 of 14 other Post-Concussion Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Post-Concussion Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Personalized Brain Stimulation to Treat Chronic Concussive Symptoms
RECRUITING · Phase 2
-
Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients With Post Concussion Syndrome (PCS)
RECRUITING · NA
-
Post-concussion Syndrome and Chiropractic
RECRUITING · NA
-
Assessment of the Efficacy of Medrol Dose Pack for Acute Post-Concussive Headaches
RECRUITING
-
Non-invasive Stimulation of the Glymphatic System for Slowing Cognitive Decline
RECRUITING · NA
-
Mobile Subthreshold Exercise Program for Concussion--R01
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI